[Influence of the delay in urinary NMP22 preanalytical processing].

Current protocols for urine-based immunoassays often require immediate stabilization to preserve biomarker integrity. Prior research has shown that delays in processing can lead to variability in results for some urinary markers. However, no prior work had resolved whether this applies to NMP22 specifically. This gap motivated a study to assess how delays in preanalytical handling affect NMP22 measurements. Understanding this could help standardize urine sample handling in clinical settings. NMP22 is used in bladder cancer diagnostics, so accurate quantification is essential. Existing knowledge suggests that biomarkers like NMP22 may degrade without proper stabilization. But the exact time window for stabilization remains unclear. This study aimed to test whether delays in adding stabilization solution impact NMP22 levels.

The aim of this study was to determine if delays in adding stabilization solution to urine samples affect NMP22 measurement accuracy. The specific problem addressed is the variability in sample handling protocols across clinical settings. The motivation stems from a need to standardize urine processing for NMP22 immunoassays. Current guidelines suggest immediate stabilization, but this may not always be feasible in practice. The researchers sought to test whether delays up to 150 minutes impact NMP22 results. This could help reduce sample rejection rates and improve diagnostic reliability. The study focused on a range of clinical conditions to ensure findings are broadly applicable. The goal was to provide evidence for more flexible handling protocols without compromising test accuracy.

The study used 28 voided urine samples from various diagnostic groups. Samples were collected from bladder cancer patients, those with urinary tract infections, lithiasis, and healthy individuals. Each sample was divided into four aliquots processed at 0, 30, 90, and 150 minutes after collection. All samples were stored at room temperature until stabilization. Stabilization solution was added at the specified time points. After stabilization, samples were refrigerated until analysis. NMP22 levels were measured using the IMMULITE One immunoassay system. The design allowed comparison of NMP22 levels across different delays in processing.

NMP22 levels showed no significant differences across the four time points tested. The delay in adding stabilization solution up to 150 minutes did not affect NMP22 measurements. The study found consistent results even when stabilization was delayed by two and a half hours. This suggests that NMP22 remains stable in urine for extended periods before processing. The lack of variability indicates that NMP22 is not sensitive to short-term delays in stabilization. The findings apply across all diagnostic groups included in the study. The stability was observed regardless of the underlying condition of the patient. These results suggest that NMP22 immunoassays can tolerate delays in sample processing.

The authors concluded that delays in adding stabilization solution to urine samples do not affect NMP22 results. Their findings suggest that NMP22 remains stable for up to 150 minutes after collection. This conclusion is based on the observed consistency in NMP22 levels across all time points. The study supports the possibility of more flexible handling protocols for NMP22 testing. The results may help reduce the need for immediate stabilization in clinical settings. The authors propose that this could improve diagnostic workflow without compromising accuracy. They suggest that these findings could be useful in standardizing urine sample handling procedures. The study does not claim that longer delays beyond 150 minutes would have the same effect.